Results 171 to 180 of about 6,879 (203)
Some of the next articles are maybe not open access.

Rimonabant Sanofi-Synthélabo.

Current opinion in investigational drugs (London, England : 2000), 2004
Rimonabant, an antagonist of central cannabinoid type 1 (CB1) receptors, is being developed by Sanofi-Synthélabo for the potential treatment of obesity and as a potential smoking cessation agent. Phase III trials were initiated for obesity in August 2001 and were ongoing in September 2003.
Jose R, Fernandez, David B, Allison
openaire   +1 more source

Rimonabant

Reactions Weekly, 2013
openaire   +1 more source

The Hope and Fear of Rimonabant

JAMA, 2008
John S, Rumsfeld   +1 more
openaire   +2 more sources

Efficacy and Safety of the Weight-Loss Drug Rimonabant: A Meta-Analysis of Randomised Trials

Lancet, The, 2007
Arne Astrup   +2 more
exaly  

Rimonabant Hydrochloride

Drugs of the Future, 2005
null Sorbera, L.A.   +2 more
openaire   +1 more source

Rimonabant ☆

2017
openaire   +1 more source

Home - About - Disclaimer - Privacy